KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other financing activities (2016 - 2023)

Historic Other financing activities for Travere Therapeutics (TVTX) over the last 13 years, with Q4 2023 value amounting to -$259000.0.

  • Travere Therapeutics' Other financing activities changed N/A to -$259000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was -$259000.0, marking a year-over-year increase of 7693.68%. This contributed to the annual value of -$1.4 million for FY2023, which is 11398.5% down from last year.
  • According to the latest figures from Q4 2023, Travere Therapeutics' Other financing activities is -$259000.0.
  • Travere Therapeutics' Other financing activities' 5-year high stood at $9.5 million during Q1 2022, with a 5-year trough of -$6.1 million in Q4 2021.
  • Its 4-year average for Other financing activities is $396000.0, with a median of -$259000.0 in 2023.
  • Per our database at Business Quant, Travere Therapeutics' Other financing activities crashed by 1553.61% in 2019 and then plummeted by 16573.6% in 2023.
  • Travere Therapeutics' Other financing activities (Quarter) stood at $772000.0 in 2019, then crashed by 890.67% to -$6.1 million in 2021, then soared by 106.45% to $394000.0 in 2022, then plummeted by 165.74% to -$259000.0 in 2023.
  • Its last three reported values are -$259000.0 in Q4 2023, -$260000.0 for Q3 2023, and -$259000.0 during Q2 2023.